Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

127 results about "Th polarization" patented technology

Compositions and methods for priming monocytic dendritic cells and t cells for th-1response

The present invention provides compositions and methods for inducing maturation of immature dendritic cells (DC) and for priming those cells for inducing a type 1 immune response. The present invention also provides dendritic cell populations useful for activating and for preparing T cells polarized towards production of type 1 cytokines and / or a type 1 response. Similarly, activated, polarized T cell populations, and methods of making the same are provided.
Owner:NORTHWEST BIOTHERAPEUTICS INC

Mature type-1 polarized dendritic cells with enhanced IL-12 production and methods of serum-free production and use

The present invention discloses novel dendritic cell maturation-inducing cytokine cocktails, and methods for inducting type-1 polarized dendritic cells in serum-free conditions which enhance the desirable properties of DC1s generated in serum-supplemented cultures. The invention further discloses methods and systems using IFNγ and other ligands of the IFNγ receptor, in combination with IFNα (or other type I interferons), poly I:C, and other IFNα (and IFNβ) inducers to enhance the IL-12-producing properties of dendritic cells. More specifically, the present invention discloses type-1 polarized dendritic cells that have a unique combination of a fully-mature status and an elevated, instead of “exhausted”, ability to produce IL-12p70. allows for the generation of fully-mature DC1s in serum-free AIM-V medium. The invention discloses systems that use the foregoing products and methods to facilitate the clinical application of DC1-based vaccines and the identification of novel factors involved in the induction of Th1 and CTL responses by DC1.
Owner:KALINSKI PAWEL

Assays for detection of bioactive compounds that interact with heat shock protein 90

InactiveUS20070178537A1Low costHigh ATPase activityCompound screeningHybrid immunoglobulinsCell based assaysHsp90 binding
A method for evaluation of molecules to identify those that can act as therapeutic inhibitors of Hsp90 makes use of a fluorescence polarization (FP) assay and a cell based assay, either individually or in combination. The FP assay uses a fluorescently-labeled Hsp90 binding agent and measure the degree of fluorescence polarization relative to the standard. A decrease in the degree of polarization indicates that fluorescently-labeled Hsp90 binding agent has been wholly or partially displaced by a candidate molecule, and identifies the molecule as having activity as an inhibitor of Hsp90. The cell based assay tests for decrease is an Hsp90-dependent activity of normal or tumor cells.
Owner:MEMORIAL SLOAN KETTERING CANCER CENT

Methods for In Vivo Evaluation of Pulmonary Physiology And/Or Function Using NMR Signals of Polarized 129Xe

In certain embodiments, methods of the present invention obtain dynamic data sets of an NMR spectroscopy signal of polarized 129Xe in a selected structure, environment, or system. The signal data can be used to evaluate: (a) the physiology of a membrane or tissue; (b) the operational condition or function of a body system or portion thereof (when at rest or under stimulation); and / or (c) the efficacy of a therapeutic treatment used to treat a diagnosed disorder, disease, or condition. Thus, the present invention provides methods for screening and / or diagnosing a respiratory, cardiopulmonary disorder or disease such as chronic heart failure, and / or methods for monitoring the efficacy of therapeutics administered to subject to treat the disorder or disease.
Owner:POLAREAN

Water extract of antrodia camphorata for immunostimulatory effect and preparation method thereof

A preparation method for a water extract of the fruiting body of Antrodia camphorata (ACW) is provided. The method includes steps of: (a) providing the fruiting body; and (b) boiling the fruiting body in water to obtain the water extract. This polysaccharide-rich water extract from A. camphorata induces the maturation of dendritic cells, enhances T cell proliferation and INF-γ production, and polarizes them toward the Th1 pathway. ACW can be effectively applied in cancer immunotherapy.
Owner:KAOHSIUNG MEDICAL UNIVERSITY

Method and system for determining kidney failure

InactiveUS20030083585A1Efficient and accurate means of determining kidney failure in a patientFailed measurementElectrotherapyElectrocardiographyProgressive renal failureMedical device
A method of determining kidney failure in a patient using an implantable medical device is described. In one embodiment, a first magnitude of a first polarization signal is measured. An additional magnitude of an additional polarization signal is measured after a first interval. A deflection differential between the first magnitude and the additional magnitude is determined and kidney failure in the patient is determined when the deflection differential is greater than an established threshold.
Owner:MEDTRONIC INC

Method for promoting macrophages to polarize to M1 type by utilizing piezoelectric effect and application

The invention relates to a method for promoting macrophages to polarize to M1 type by utilizing a piezoelectric effect and application. According to the method, a piezoelectric material is combined with ultrasound to trigger non-contact and non-invasive electrical stimulation, and the important role of the electrical stimulation in immune regulation is verified; by taking the piezoelectric material as a cell culture substrate, and combining with ultrasound stimulation, M1 type polarized macrophages are cultured in vitro, and compared with a common biochemical method, the method does not need to introduce external polarized macrophages (PMAPs); and by utilizing the commercialized piezoelectric material, macrophages can be rapidly promoted to polarize to the M1 type by a method for applyingthe ultrasound; The method has a good effect of promoting the macrophages to polarize to the M1 type by utilizing the piezoelectric effect, and has the clinical application potential of tumor immunotherapy and anti-infective therapy. The method disclosed by the invention can be used for producing the M1 type polarized macrophages in batches so as to promote application of the piezoelectric material in immunotherapy.
Owner:SHANDONG UNIV

Mature type-1 polarized dendritic cells with enhanced il-12 production and methods of serum-free production and use

InactiveUS20090004157A1Improve propertiesEnhance IL-12-producing propertyBiocideArtificial cell constructsDendritic cellSerum free
The present invention discloses novel dendritic cell maturation-inducing cytokine cocktails, and methods for inducting type-1 polarized dendritic cells in serum-free conditions which enhance the desirable properties of DC1s generated in serum-supplemented cultures. The invention further discloses methods and systems using IFNγ and other ligands of the IFNγ receptor, in combination with IFNα (or other type I interferons), poly I:C, and other IFNα (and IFNβ) inducers to enhance the IL-12-producing properties of dendritic cells. More specifically, the present invention discloses type-1 polarized dendritic cells that have a unique combination of a fully-mature status and an elevated, instead of “exhausted”, ability to produce IL-12p70. allows for the generation of fully-mature DC1s in serum-free AIM-V medium. The invention discloses systems that use the foregoing products and methods to facilitate the clinical application of DC1-based vaccines and the identification of novel factors involved in the induction of Th1 and CTL responses by DC1.
Owner:PAWEL KALINSKI

Application of TIGIT-ECD recombinant protein in resisting allogeneic immunological rejection

The invention provides an application of a TIGIT-ECD recombinant protein in resisting allogeneic immunological rejection. The amino acid sequence of the recombinant protein TIGIT-ECD is shown as SEQ ID NO:1. The nucleotide sequence coding the recombinant protein TIGIT-ECD is shown as SEQ ID NO:2. The recombinant protein is capable of effectively regulating macrophage polarization by activating a TIGIT-CD155 signal path, and contributes to inducing allogeneic graft tolerance. Therefore, the recombinant protein TIGIT-ECD can serve as a graft rejective reaction inhibitor, and can also be appliedto preparing drugs for preventing and treating the graft rejective reaction.
Owner:FOURTH MILITARY MEDICAL UNIVERSITY

Recombinant Bacteriophages Useful for Tissue Engineering

The invention provides for a composition comprising a genetically engineered bacteriophage capable of guiding cell growth and polarization via signaling peptides and directionally aligned structures. The invention provides for modified bacteriophage and its uses thereof. The present invention also provides for genetically engineered phage capable of guiding cell growth, migration and / or alignment, providing essential biological effects including proliferation and / or differentiation, which can be performed by expressing specific biological motifs, such as the amino acid sequences RGD, IKVAV, DGEA and HPQ, on their coat proteins, on which functional DNA, proteins and cells can be conjugated and / or fixed thereon.
Owner:RGT UNIV OF CALIFORNIA

Methods for in vivo evaluation of physiological conditions and/or organ or system function including methods to evaluate cardiopulmonary disorders such as chronic heart failure using polarized 129Xe

In certain embodiments, methods of the present invention obtain NMR spectroscopy signal data that corresponds to the behavior of the polarized 129Xe at a selected site(s) in selected environments in vivo. The gas exchange signal data can be used to evaluate: (a) the thickness of a barrier, such as a membrane, lining, wall or width of a lumen; (b) the operational condition or function of a membrane, body system or portion thereof; (c) cerebral perfusion; and / or (c) the efficacy of a therapeutic treatment used to treat a diagnosed disorder, disease, or condition. Thus, the present invention provides methods for screening and / or diagnosing a disorder or disease, and / or methods for monitoring the efficacy of therapeutics administered to subject to treat a disorder or disease.
Owner:POLAREAN

Nanoparticle coated with ferroferric oxide by macroporous organic silicon oxide and preparation method and application thereof

The invention discloses a nanoparticle coated with ferroferric oxide by macroporous organic silicon oxide and a preparation method and application thereof. An organic silicon oxide shell layer outsidethe nanoparticle has a large radial channel, and ferroferric oxide coated at an inner layer has superparamagnetism. The nanoparticle is synthesized in an oil-water two-phase system by using a surfactant as a template, and using organic and inorganic silane as a silicon source precursor under the action of oil regulation. The nanoparticle has a complete spherical structure, uniform size, and gooddispersibility, the nanoparticle with a macroporous structure is loaded with an antigen to be used for tumor immunotherapy, which not only improves the phagocytosis of dendritic cells (DCs) to the antigen, and can simultaneously stimulate the maturing of more antitumor T cells, thereby causing M1 type polarization of tumor associated macrophage, and showing an excellent anti-tumor effect, therefore a novel nano medical integrated platform for tumor immunotherapy is expected to be established.
Owner:NANJING UNIV OF POSTS & TELECOMM

Sample analyzing method and sample analyzer

Disclosed is a sample analyzing method comprising: flowing a measurement specimen prepared by mixing a sample and reagent through a flow cell; irradiating particles in the measurement specimen flowing through the flow cell with linearly polarized light and thereby producing scattered light; detecting a change of polarization condition of the scattered light produced by the particles; and discriminating erythrocytes from crystals in the measurement specimen based on the change of polarization condition.
Owner:SYSMEX CORP

M1 type macrophage exosome vaccine as well as preparation method and application thereof

ActiveCN113398258AEnhanced Immunotherapy EfficiencySignificant immune activationCell dissociation methodsCancer antigen ingredientsOncologyTumor antigen
The invention provides an M1 type macrophage exosome vaccine as well as a preparation method and application thereof. The M1 type macrophage exosome vaccine is characterized in that an exosome vaccine M1Ag-Exos is obtained by enabling M1 type macrophages to uptake a specific tumor antigen Ag and then extracting an exosome of the M1 type macrophages carrying the tumor antigen Ag. According to the M1 type macrophage exosome vaccine, the exosome vaccine capable of adjusting the tumor immune microenvironment is constructed to enhance the immunotherapy efficiency, and polarization of tumor-related macrophages and the remarkable immune activation effect of a tumor vaccine are achieved through the M1 type macrophage exosome; the tumor-related macrophages are polarized into M1 type, so that the macrophages are converted from a state of promoting tumor invasion and metastasis by immunosuppression into a state of supporting tumors by immunity; meanwhile, through immunoregulation on the tumor microenvironment, the tumor vaccine can promote proliferation and activation of T cells more efficiently, and growth and metastasis of the tumors are effectively inhibited.
Owner:HEBEI UNIVERSITY

Macrophage exclusive chimeric antigen receptor, controllable polarized mononuclear/macrophage for expressing macrophage exclusive chimeric antigen receptor and preparation method and application thereof

The invention provides a macrophage exclusive chimeric antigen receptor, a controllable polarized mononuclear / macrophage for expressing the macrophage exclusive chimeric antigen receptor, and a preparation method and application thereof, and relates to the field of biotechnology. The invention provides a chimeric antigen receptor which comprises an extracellular antigen binding domain, a transmembrane domain and an intracellular activation domain which are sequentially connected, and the extracellular antigen binding domain comprises signal peptide and / or scFv and can specifically recognize cell membrane surface protein EGFRvIII specifically expressed by GBM; the transmembrane domain comprises CD8alpha which linking the extracellular antigen binding domain and the intracellular activation domain; an intracellular activation domain comprises TIR, CD3ZETA or GM-CSFRalpha / beta and promotes polarization of macrophages to M1, the chimeric antigen receptor is introduced into the macrophages, the macrophages are endowed with a targeted killing effect on GBM, and the M1 polarization state of the macrophages is effectively promoted and maintained.
Owner:ZHEJIANG UNIV

Type 1 polarized dendritic cells and inducing method and application thereof

The invention provides type 1 polarized dendritic cells and an inducing method and application thereof. A novel DC1 preparation method is built through the assistant function of Natural Killer cells of umbilical cord blood in the adaptive immunity activating process of DCs, and in the preparation process, usage of cell factors is reduced, the cost is lowered, and quality control is improved. The invention further provides a method for applying the prepared DC1s to preparation of CTLs with the tumor antigen specificity; after the DC1s are loaded with tumor specific antigens, part of the cells are transfused to a patient body, the other part of the cells are used for in-vitro inductive cytotoxic T lymphocytes (CTL) with the tumor antigen specificity, and the immunoreaction of the tumor specificity is activated through the mode of combining active induction with passive induction in vivo and vitro.
Owner:SHANGHAI LONGYAO BIOTECH CO LTD

Methods and compositions for needleless delivery of macromolecules

Methods and compositions for needleless delivery of macromolecules to the bloodstream of a subject are provided herein. In one aspect, the invention provides a delivery construct, comprising a receptor binding domain, a transcytosis domain, a macromolecule to be delivered to a subject, and a cleavable linker. Generally, the cleavable linker is cleavable by an enzyme present in higher concentration at or near the basal-lateral membrane of a polarized epithelial cell or in the plasma than elsewhere in the body, for example, at the apical side of the polarized epithelial cell. In other aspects, the invention provides nucleic acids encoding delivery constructs of the invention, kits comprising delivery constructs of the invention, cells expressing delivery constructs of the invention, and methods of using delivery constructs of the invention.
Owner:TRINITY ASSIGNMENT FOR THE BENEFIT OF CREDITORS

Method for efficiently and sequentially inducing macrophages to be polarized in vitro

The invention discloses a method for efficiently and sequentially inducing macrophages to be polarized in vitro. The method comprises the following steps of: S1, carrying out multiplication culture onTHP-1 cells by using an RPMI1640 culture medium containing 10% of FBS and beta-mercaptoethanol; S2, carrying out pretreatment before induction on the THP-1 cells by using PBS containing HPL and a culture medium; S3, in an RPMI1640 culture medium which contains 5% of HPL and does not contain the beta-mercaptoethanol, slowly inducing the THP-1 cells by adopting low-concentration PMA so as to enablethe THP1 cells to be differentiated into M0 macrophages in an adherence mode, and then removing the PMA; and S4, in an RPMI1640 culture medium which contains 5% of HPL and does not contain the beta-mercaptoethanol, inducing M0 macrophages for more than 72 hours by using LPS/IFN-gamma, so that the M0 macrophages are polarized into M1; or inducing the M0 macrophages for more than 72 hours by usingIL-4/IL-13, so that the M0 macrophages are polarized into M2 macrophages. Compared with the prior art, the method disclosed by the invention has the advantages that firstly, the THP-1 cells are slowlyinduced by adopting the low-concentration PMA, so that the immatureness state of the M0 type macrophages differentiated from the THP1 cells can be guaranteed; and then the optimal induced polarization time of the subsequent M1/M2 type macrophages is over 72 hours, so that the polarization state of the M1/M2 type macrophages is guaranteed. Meanwhile, the differentiation process is carried out in an environment without animal-derived components, so that the polarization efficiency of the macrophages can be effectively ensured.
Owner:AFFILIATED HOSPITAL OF ZUNYI UNIV

In-vitro induction regulatory macrophage and preparation method and application

The present invention discloses an in-vitro induction regulatory macrophage and a preparation method and application, the preparation method comprises the following steps: rat bone marrow cells are taken and cultured, during culture, a recombinant rat macrophage colony stimulating factor is added into a culture medium to obtain wall adherent growth macrophages; in the culture medium, all-transretinoic acid and tumor transforming growth factor-beta are added, the culture is continued, and the macrophage is induced for polarization to obtain the regulatory macrophage. The in-vitro induction regulatory macrophage can be used for treatment of ocular autoimmune diseases. The all-transretinoic acid and TGF-beta are used for in-vitro induction of R-M phi, and the disadvantages of being unstable and prone to M1-type pro-inflammatory macrophage differentiation in the prior art can be avoided, stability of R-M phi can be well kept, and R-M phi anti-inflammatory and immunomodulatory stability can be effectively maintained.
Owner:ZHONGSHAN OPHTHALMIC CENT SUN YAT SEN UNIV

Compositions and methods for priming monocytic dendritic cells and t cells for th-1 response

The present invention provides compositions and methods for inducing maturation of immature dendritic cells (DC) and for priming those cells for inducing a type 1 immune response. The present invention also provides dendritic cell populations useful for activating and for preparing T cells polarized towards production of type 1 cytokines and / or a type 1 response. Similarly, activated, polarized T cell populations, and methods of making the same are provided.
Owner:NORTHWEST BIOTHERAPEUTICS INC

Modified proteins, isolated novel peptides,and uses thereof

InactiveUS20040091964A1AmenableModulate transporter activityAntibacterial agentsFungiPolarized cellChemo therapy
The present invention provides several modified ABC transporter polypeptides that exhibit novel localization in the plasma membrane of polarized and non-polarized cells. The modified ABC transporter of the invention comprises the amino acid sequence of a native apically targeted ABC transporter, in particular cMOAT, MDR3 or MRP4, wherein the terminal tripeptide T-K-F motif of said native ABC transporter is mutated. The isolated modified ABC transporter polypeptide of the invention, and the nucleotide sequence encoding said polypeptide, have utility in the following applications: First, they are used to induce a drug resistant phenotype in a cell. Second, they are used to protect non-polarized cells during chemotherapy and other therapeutic applications. Third, they are used to produce novel cell lines that are used to screen for novel agonists or antagonists of the corresponding native ABC transporter polypeptides.
Owner:BOARD PHILLIP +1

Method for adjusting polarization state of macrophage

The invention relates to the technical field of biological medicines and particularly discloses a method for adjusting a polarization state of a macrophage. The method comprises the step of adopting an over-expressed HIMF gene to infect the macrophage or adopting specific siRNA to knock down or integrally knock out an HIMF gene in the macrophage. Through the mode, the macrophage is infected by adopting the over-expressed HIMF gene or the HIMF gene in the macrophage is knocked down or integrally knocked out by adopting the specific siRNA, and functions of macrophages of different polarization types are influenced, so that the occurrence and development of inflammations are inhibited, and the occurrence of myocardial infarction is delayed.
Owner:SHENZHEN INST OF ADVANCED TECH CHINESE ACAD OF SCI

Fullerene nanoparticles for enhancing antitumor immunotherapy

The invention relates to an application of fullerene nanoparticles in preparation of a drug for tumor immunotherapy. The fullerene nanoparticles comprise an amino acid modified fullerene water-solublemodifier; the drug can activate immune cells, polarize tumor-associated macrophages and / or improve T lymphocyte infiltration at a tumor site; and the treatment effect of an antitumor immunity drug PD-L1 inhibitor is enhanced.
Owner:INST OF CHEM CHINESE ACAD OF SCI +1

Medium and method for proliferation and differentiation of alveolus organoids

InactiveCN112458039AContinuous proliferationContinuous differentiationCell dissociation methodsCulture processEpitheliumDisease
The invention discloses a medium and method for proliferation and differentiation of alveolus organoids. The method disclosed by the invention can reliably obtain the human alveolus organoids with relatively low cost and relatively high efficiency, and is beneficial to large-scale popularization and use of the alveolus organoids in the biomedical industry. The alveolus organoids related to the invention can remedy all the defects of a traditional alveolar in-vitro model at present, thereby meeting the four basic requirements of an alveolus disease model: (1) the alveolus organoids have the capabilities of sustained proliferation and sustained differentiation; (2) a complete tissue structure (monolayer polarized cystic epithelium) and normal physiological functions (for example secretion ofan alveolus surfactant, an alveolus innate immune process and the like) of alveoli in vivo can be retained or reproduced; (3) the alveolus organoids have good operability, and can be repeated cryopreserved, resuscitated and passaged like a cell line; and (4) the alveolus organoids come from human tissue and reflect individual differences.
Owner:ZHEJIANG UNIV

TH1/TH2 polarizing vaccines

ActiveUS20120195893A1Antibacterial agentsAntibody mimetics/scaffoldsT helper 2T helper 1
The present invention relates to recombinant chimeric molecules that are capable of providing T cell receptor (TCR) interaction and costimulation for activation and differentiation of pathogen-specific T cells toward effector T helper 1 (Th1) or T helper 2 (Th2) cells. The chimera may capable of elicit antibodies against pathogen-specific B cell epitope(s). The present invention also relates method of using these chimeric molecules in whole or as a component of a vaccine.
Owner:THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY

Method for regulating polarization state of macrophages

The invention provides a method for regulating the polarization state of macrophages. The method comprises the step of activating cholinergic anti-inflammatory pathways of the macrophages by adoptingcholinergic anti-inflammatory pathway agonists and / or vagus nerve electrical stimulation signals. According to the method in the invention, the cholinergic anti-inflammatory pathway agonists are adopted to stimulate the macrophages in vitro; or the electrical stimulation signals are adopted to stimulate vagus nerves in vivo; therefore, the cholinergic anti-inflammatory pathways are activated; polarization of M1 type macrophages is inhibited; polarization of M2 type macrophages is promoted; a regulating effect on macrophage polarization types is achieved; and the method has the important significance in the aspects of specifically regulating the functions of the polarized macrophages and diseases caused by the polarized macrophages.
Owner:SHENZHEN INST OF ADVANCED TECH CHINESE ACAD OF SCI

Method for efficiently preparing linear polarization tree dendritic cells and application of method

The invention provides a method for efficiently preparing DC1 cells through T cell culture medium supernatant. Peripheral blood of tumor patients or healthy people is processed, immature DC cells are separated out, and a product where DC1 cells are enriched is obtained through oriented induction. The product prepared in this way has the capacity for efficiently inducing tumor specific CTL cells and Th1 cells, and can be used for optimizing the clinical effect of the tumor immunity treatment technology. In addition, the invention further provides a method for using the prepared DC1 cells for preparing tumor antigen specific CTL cells. After the DC1 cells are loaded with tumor specific antigens, one part of the DC1 cells are conveyed back into patient bodies, the other part of the DC1 cells are used for in-vitro tumor antigen specific induction cytotoxic lymphocytes (CTL), and the specific immune reaction of tumors is activated through an in-vivo / in-vitro and active induction / passive induction combined mode.
Owner:SHANGHAI LONGYAO BIOTECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products